The Antinociceptive Effects of Tramadol and/or Gabapentin on Rat Neuropathic Pain Induced by a Chronic Constriction Injury
Preclinical Research The current work evaluates the interaction between two commonly used drugs, tramadol (Tra) and gabapentin (Gbp). Dose‐response curves (DRC) and isobolographic analysis were used to confirm their synergistic antihyperalgesic and anti‐allodynic responses in a rat neuropathic pain...
Saved in:
Published in: | Drug development research Vol. 77; no. 5; pp. 217 - 226 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Blackwell Publishing Ltd
01-08-2016
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Preclinical Research
The current work evaluates the interaction between two commonly used drugs, tramadol (Tra) and gabapentin (Gbp). Dose‐response curves (DRC) and isobolographic analysis were used to confirm their synergistic antihyperalgesic and anti‐allodynic responses in a rat neuropathic pain model involving chronic constriction injury of the sciatic nerve and in von Frey and acetone tests. Tra and Gbp produced dose‐dependent antihyperalgesic and anti‐allodynic effects. Dose‐response studies of combinations of Tra and Gbp in combination showed the DRC was leftward‐shifted compared to the DRCs for each compound alone. One combination demonstrated both antihyperalgesic and anti‐allodynic effects greater than those observed after individual administration. The remaining combinations demonstrated an additive effect. The Tra+Gbp combination demonstrated a potentiative effect with smaller doses of Tra. Additionally, it was determined lethal dose 50 (LD50) of Tra alone and tramadol + Gbp 10 using mice to 48 h post administration. The DRC (death) were similar for Tra alone and in Tra in combination, despite the improved effectiveness of Tra in the presence of GBP, 10 mg/kg. A combination of these drugs could be effective in neuropathic pain therapy because they can produce potentiative (at a low dose) or additive effects. Drug Dev Res 77 : 217–226, 2016. © 2016 Wiley Periodicals, Inc. |
---|---|
Bibliography: | ark:/67375/WNG-QZLK04H5-7 ArticleID:DDR21313 istex:5A3CC972FA308CCC48ADF31EC8EEFACD855EA081 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0272-4391 1098-2299 |
DOI: | 10.1002/ddr.21313 |